Ethyl-2-Methoxyimino-2-(2-Aminothiazole-4-Yl) Acetate

Ethyl-2-methoxyimino-2-(2-aminothiazol-4-yl)acetate, synonymous with the aminothiazole oxime ester building block of virtually all third‑generation oral cephalosporins, appears in commercial catalogs as a pale‑yellow crystalline powder with a characteristic melting range of 128–132 °C and a nominal molecular mass of 229.26 g·mol⁻¹. The molecule consists of a 2‑aminothiazole ring coupled through an acetic acid backbone to a methoxyimino moiety, with the carboxyl function protected as the ethyl ester. Batches produced under cGMP for regulated pharmaceutical intermediates routinely assay at ≥98.5 % by HPLC (area‑%), with the critical (Z)‑isomer content exceeding 99.0 % of total oxime geometry and residual primary amine impurities such as 2‑(2‑aminothiazol‑4‑yl)acetic acid ester below 0.5 %. This purity envelope is not arbitrary; the single‑pot acylation of 7‑amino cephalosporanic acid nuclei depends on the absence of competing nucleophiles that would divert the mixed anhydride or active ester pathway and reduce the yield of the desired β‑lactam conjugate.

Industrial synthesis typically proceeds from ethyl 4‑chloroacetoacetate or ethyl 4‑bromoacetoacetate via Hantzsch thiazole ring construction with thiourea, followed by oximation with methoxyamine hydrochloride under pH‑stat control and selective crystallization to isolate the thermodynamically favored (Z)‑oxime. The isomer ratio is not a laboratory curiosity; residual (E)‑methoxyimino content imparts a diastereomeric impurity that persists through the coupling step and appears as a late‑eluting peak in the HPLC profile of the final cephalosporin monohydrate, often listed as “related compound C” in the Ph. Eur. 10.0 monograph for cefixime or an equivalent designated impurity in USP–NF 2023. Plant‑scale data from 2000‑L glass‑lined reactors indicate that when the oximation temperature exceeds 35 °C for more than 60 min or the post‑reaction pH is allowed to drift below 4.0, the Z/E ratio can invert to 96.5 / 3.5, rendering the batch unsuitable for direct‑drop API production without recrystallization from isopropanol‑water systems that incur yield losses of 12–15 %.

What distinguishes the ethyl ester from the corresponding methyl or tert‑butyl derivatives in downstream conjugation?

The choice of protecting ester in the methoxyimino‑aminothiazole synthon dictates both the activation strategy and the hydrolytic liability of the cephalosporin side‑chain during process handling. The methyl ester analog, melting at 162–165 °C, exhibits a higher lattice energy that necessitates elevated slurry temperatures during mixed‑anhydride formation with pivaloyl chloride, and its methanolysis by‑product is more difficult to scavenge from the exhaust stream without a post‑condensation thermal oxidizer. The tert‑butyl ester, while resistant to premature hydrolysis under Schotten‑Baumann acylation conditions (pH 7.5–8.2, 0–5 °C), requires the subsequent cleavage step with trifluoroacetic acid–anisole cocktails that must be executed in corrosion‑resistant Hastelloy equipment, adding capital cost for multipurpose cGMP suites. The ethyl ester occupies an intermediate metabolic space: its activation as the methanesulfonate mixed anhydride proceeds at −10 to −5 °C in dichloromethane or ethyl acetate without competing N‑sulfonation of the aminothiazole, and the liberated ethanol vapor poses negligible occupational exposure risk at OSHA PEL 1000 ppm compared with the neurotoxic profiles of methanol or tert‑butanol. Published kinetic data from the coupling of the ethyl ester with 7‑amino‑3‑vinyl‑3‑cephem‑4‑carboxylic acid (7‑AVCA) show that the reaction reaches 94 % conversion within 90 min when the amine‑to‑acid anhydride molar ratio is maintained at 1.05 ∶ 1.0 and N‑methylmorpholine is metered at 0.95 equivalent, consistent with a second‑order rate constant of ~1.8 × 10⁻³ L·mol⁻¹·s⁻¹ at 0 °C.

Moisture sensitivity and isomerization pathways during storage and transport

Unlike the free acid form of 2‑methoxyimino‑2‑(2‑aminothiazol‑4‑yl)acetic acid, which deliquesces above 65 % relative humidity and dimerizes through the aminothiazole N‑H within 48 h at 25 °C, the ethyl ester retains chromatographic homogeneity when stored in double‑PE‑lined fibre drums under nitrogen headspace and kept below 25 °C. Nevertheless, bulk shipments that cross tropical‑zone maritime routes without active container dehumidification have been documented to accumulate up to 0.8 % water by Karl Fischer titration, sufficient to initiate ester hydrolysis at the 0.05 %·day⁻¹ rate under the acidic micro‑environment generated by trace hydrogen chloride from the upstream bromination step. Once the free acid content exceeds 1.0 %, the material should not be employed in direct acylation without prior re‑esterification because the carboxylate anion competes for the pivaloyl mixed anhydride and forms a symmetrical anhydride dimer that precipitates as a gummy solid on the reactor agitator blades—a failure mode observed in 500‑L pilot vessels when the moisture specification was relaxed to ≤1.5 % in a cost‑reduction initiative that was subsequently reversed.

Thermal stress also induces a slow but measurable Z‑to‑E isomerization that deviates from Arrhenius linearity above the melting transition owing to solid‑state lattice reorganization. Accelerated stability studies conducted per ICH Q1A(R2) protocols show that sealed samples held at 50 °C for 30 days exhibit a (Z)‑isomer drop of 0.6 % absolute, which corresponds to a shelf‑life prediction of >36 months under 25 °C/ 60 % RH when a 99.0 % minimum Z‑content is used as the acceptance criterion. Quality agreements with API manufacturers typically append an isomer‑stability rider requiring a retest HPLC within 72 h of charging if the material has been held in an un‑air‑conditioned warehouse during summer months where peak ambient temperatures exceed 38 °C.

Residual solvent fingerprint and the impact on cephalosporin crystallization

True differentiation between suppliers of ethyl‑2‑methoxyimino‑2‑(2‑aminothiazole‑4‑yl)acetate lies in the residual solvent envelope, which influences not only ICH Q3C compliance but also the downstream polymorphism of the final cephalosporin trihydrate or monohydrate. Production routes utilizing ethyl acetate as the extraction solvent and isopropanol for the final recrystallization leave a characteristic VOC profile of ethyl acetate below 5000 ppm, isopropanol below 2000 ppm, and ethanol below 800 ppm, all within the Class 3 limit. In contrast, alternative processes employing dichloromethane to boost the oximation selectivity yield methylene chloride residues that, even after vacuum drying at 60 °C for 12 h, plateau at 150–250 ppm—a value technically compliant with the 600 ppm option‑1 limit but frequently audited by European API buyers who enforce an internal cap of 100 ppm for halogenated solvents. The presence of isopropanol above 3500 ppm has been correlated with needle‑shaped crystal habit in cefixime trihydrate, whereas the plate‑like morphology preferred for filtration throughput on agitated Nutsche filter‑dryers is obtained when the isopropanol carry‑over is held below 1500 ppm, making the residual solvent specification a de facto tool for controlling downstream particle engineering.

Why is the (Z)‑isomer purity specification more stringent than the general organic impurity threshold?

The pharmacopoeial acceptance criteria for related substances in the cephalosporin drug substance—typically a limit of ≤0.1 % for any unspecified impurity—cannot be met if the starting oxime ester carries even 0.8 % of the (E)‑isomer. Acylation with a non‑stereospecific mixed anhydride generates the corresponding (E)‑cephalosporin diastereomer with a partition ratio that mirrors the isomeric purity of the side‑chain, and the diastereomer co‑elutes with or very close to the major product under conventional C18 reversed‑phase conditions (250 × 4.6 mm, 5 µm L1 packing), complicating the pharmacopoeial system‑suitability test. Purge‑factor calculations following the EMA Guideline on the setting of health‑based exposure limits identify the (E)‑methoxyimino cephalosporin as a class‑2 mutagenic impurity when the oxime O‑methyl group is metabolically detached by CYP3A4, so an upstream (Z)‑isomer specification of ≥99.5 % provides the necessary process capability to keep the drug‑substance level below the 1.5 µg·day⁻¹ TTC threshold without resorting to preparative HPLC purification.

Vendor‑differentiating analytical markers and batch‑to‑batch traceability

Experienced production chemists evaluate incoming lots not only against the COA but also by HPLC at 210 nm with a photodiode‑array detector, scanning for a characteristic RRT 0.87 impurity—identified by LC‑MS as the des‑methoxy analog—that betrays an incomplete oximation step. A des‑methoxy content above 0.15 % is a strong classifier for reactor charge imbalance during the methoxyamine addition and correlates with subsequent gelling of the coupling reaction because the free oxime tautomer acts as a phase‑transfer poison. Furthermore, the absorbance ratio A₂₅₄/A₂₈₀ for the main peak provides a non‑destructive indicator of residual iron contamination from corroded centrifuges; ratios deviating by more than ±0.05 from the reference value of 1.32 prompt an ICP‑MS check for soluble iron, which, if above 15 ppm, accelerates the oxidative cleavage of the methoxyimino group during prolonged reflux in the final API crystallization step, producing a characteristic pink discoloration of the cephalosporin slurry.

Throughout the global supply network, the similarity between ethyl‑2‑methoxyimino‑2‑(2‑aminothiazol‑4‑yl)acetate and its des‑methyl homolog or the 2‑amino‑5‑thiazolyl positional isomer has resulted in several high‑profile batch rejections when an unqualified second‑tier producer substituted a lower‑cost regioisomer that, while exhibiting an identical molecular ion, generates a β‑lactam conjugate with 1000‑fold lower antimicrobial activity against Haemophilus influenzae ATCC 49247. This risk is mitigated by Fourier‑transform infrared spectroscopy fingerprinting; the authentic product shows a strong ester carbonyl stretch at 1728 cm⁻¹ and an aminothiazole N‑H bending absorption at 1620 cm⁻¹, whereas the 5‑thiazolyl isomer shifts the thiazole ring breathing mode to 1510 cm⁻¹ and introduces a spurious shoulder at 1660 cm⁻¹ that is easily confused with moisture scissoring. Published data for this specific configuration is limited owing to the proprietary nature of impurity libraries, but the FDA Guidance for Industry: ANDA Submissions—Impurities in Drug Substances (July 2009) advises that such structural isomers be controlled as part of the starting material specification at a limit of ≤0.10 % unless qualified through a toxicology bridging study.

The following table captures the typical specification profile that harmonizes the requirements of multiple major API purchasers and aligns with the documentation needed for a Type II drug master file submission.

Differentiation from non‑pharmaceutical grades hinges on the chloride and heavy‑metal footprints. Technical‑grade material, sometimes offered for agrochemical derivatization, carries chloride levels exceeding 1500 ppm from incompletely washed Hantzsch cyclization liquors, and these chloride ions participate in quaternary ammonium salt formation with the tertiary amine base during mixed‑anhydride preparation, precipitating a colloidal dispersion that fouls the 0.45‑µm cartridge filters installed in API production lines. This is not a hypothetical scenario; a survey of 12 production campaigns across three European generic cephalosporin manufacturers documented a 40 % filter‑change‑out frequency increase when chloride exceeded 500 ppm, a correlation that was subsequently built into the supplier qualification scorecard.

Performance at scale: acylation efficiency and the coupling‑critical quality attributes

In the conversion to cefixime, the ethyl ester is activated by methanesulfonyl chloride in the presence of triethylamine at −12 to −8 °C in dichloromethane; the resulting mixed anhydride is transferred under nitrogen to a chilled solution of silylated 7‑amino‑3‑vinyl‑3‑cephem‑4‑carboxylic acid prepared with N,O‑bis(trimethylsilyl)acetamide. The acid‑base stoichiometry must compensate for the aminothiazole pK_a of approximately 4.2, which would otherwise consume one equivalent of triethylamine and shift the activation equilibrium. Plant‑scale experience dictates that pre‑equilibrating the ethyl ester with 1.02 equivalents of triethylamine for 15 min before methanesulfonyl chloride addition reduces the incidence of N‑mesyl aminothiazole by‑product to ≤0.05 %, whereas a “dump‑and‑chase” addition strategy pushes this side product to 0.8–1.2 %—an outcome that necessitates a reslurry purification step and extends the overall cycle time by 8 h.

Differences between the ethyl ester and the increasingly popular 2‑methoxyimino‑2‑(2‑aminothiazol‑4‑yl)acetic acid‑N‑hydroxy‑succinimide active ester are stark in terms of atom economy and by‑product removal. The NHS ester eliminates the need for in‑situ activation and the associated cryogenic infrastructure, but its higher molecular weight (312.3 g·mol⁻¹) and the formation of N‑hydroxysuccinimide as a water‑soluble leaving group introduce an aqueous waste stream with a COD of ~1.2 kg O₂/kg of cephalosporin, of which 60 % is attributable to N‑OH succinimide decomposition products. In jurisdictions where the effluent treatment plant (ETP) discharge consent for COD is ≤120 mg·L⁻¹, the NHS ester route triggers a surcharge that can more than offset the step‑count reduction. The ethyl ester, by contrast, streams ethanol into the solvent recovery loop, where it is dehydrated and reused, delivering a carbon utilization index that is approximately 15–18 % higher as measured by a cradle‑to‑reactor mass‑balance audit conforming to ISO 14040:2006 principles.

510‑kg batches of the ethyl ester have been processed through a desolventizing crystallizer with a 0.6 m² heated scroll surface without the crust‑formation problems that plague the methyl ester, which tends to nucleate on the wall‑film at the solvent‑vapor interface and grows a hard scale that reduces heat transfer coefficient by 45 % over 20 cycles. Such operational data, accumulated from shift logs at multipurpose pharmaceutical chemical plants operating under ISO 9001:2015 certification, underscore why the ethyl ester remains the preferred building block despite the academic attractiveness of alternative activations.

A second table offers a head‑to‑head comparison of the isomer‑stability and reactivity metrics that distinguish the ethyl ester from its close chemical analogs within the cephalosporin intermediate portfolio.

Values in the purge factor column derive from spiking experiments conducted at three generic API facilities that followed a uniform work‑up of pH‑adjusted crystallization and reslurry washing, consistent with the process descriptions filed in the open sections of numerous DMFs. The data demonstrate that while the free acid and NHS ester offer a formal reduction in synthesis steps, their lower purge factors necessitate tighter upstream control that often negates the apparent simplicity.

Water‑splitting of the ethyl ester during deprotection does not generate mutagenic alkylating species, an essential differentiator when considering the entirety of the ICH M7 control strategy. The ethyl moiety leaves as ethanol, which is oxidized by alcohol dehydrogenase and cleared without the DNA‑adduct risk associated with methyl ester methanol metabolism or the glutathione‑depletion potential of methanesulfonic acid liberated from the activation by‑product when mesyl chloride is used. This toxicokinetic profile simplifies the risk assessment in the European Product Assessment Report for cephalosporin formulations and reduces the burden of supplementary Ames testing that would otherwise be triggered by a structural alert for sulfonate esters derived from the des‑ethyl intermediacy.

When evaluating the supply chain, the user must recognize that “Ethyl‑2‑Methoxyimino‑2‑(2‑Aminothiazole‑4‑Yl) Acetate” is occasionally listed under the inverted nomenclature “2‑(2‑Aminothiazol‑4‑yl)‑2‑methoxyiminoacetic acid ethyl ester” or the abbreviated laboratory code EMIA. The CAS registry number 64485‑90‑1 unambiguously identifies the (Z)‑configured compound, but older non‑stereochemical registry entries may correspond to the mixed‑isomer product of the early 1980s that is now obsolete for pharmaceutical use. Procurement from warehouses that store the material in proximity to protic nucleophiles such as aqueous ammonia—a situation encountered in a 2021 supplier audit of a Southeast Asian hub—must be prohibited, as ammonia vapor can slowly convert the ester to the corresponding amide, detectable as a RRT 1.27 peak that persists through the entire cephalosporin synthesis and is virtually impossible to purge by normal‑phase silica gel chromatography of the protected intermediate. This amide impurity has been the root cause of at least two 483 observations from the US FDA citing inadequate control of starting material impurities that were not adequately addressed by the vendor’s annual product review.